UBS Group
IMDX

UBS Group’s Insight Molecular Diagnostics IMDX Stock Holding History

UBS Group’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$74.6K Buy
22,751
+19,810
+674% +$115K ﹤0.01% 7140
2025
Q4 		$22.1K Buy
2,941
+227
+8% +$1.28K ﹤0.01% 7715
2025
Q3 		$9.01K Sell
2,714
-12,651
-82% -$35.7K ﹤0.01% 8628
2025
Q2 		$46.4K Buy
15,365
+12,711
+479% +$38.4K ﹤0.01% 7833
2025
Q1 		$8.12K Sell
2,654
-60
-2% -$162 ﹤0.01% 8778
2024
Q4 		$6.46K Buy
2,714
+1,879
+225% +$5.11K ﹤0.01% 8559
2024
Q3 		$2.38K Hold
835
– – ﹤0.01% 8441
2024
Q2 		$2.46K Sell
835
-29
-3% -$80 ﹤0.01% 8355
2024
Q1 		$2.53K Sell
864
-515
-37% -$1.59K ﹤0.01% 7884
2023
Q4 		$3.45K Buy
1,379
+354
+35% +$1.09K ﹤0.01% 7968
2023
Q3 		$3.2K Sell
1,025
-1,161
-53% -$4.32K ﹤0.01% 7597
2023
Q2 		$10.1K Buy
2,186
+1,244
+132% +$6.27K ﹤0.01% 7155
2023
Q1 		$6.67K Sell
942
-899
-49% -$6.67K ﹤0.01% 7901
2022
Q4 		$11.8K Buy
1,841
+562
+44% +$6.2K ﹤0.01% 8356
2022
Q3 		$19K Buy
1,279
+279
+28% +$4.83K ﹤0.01% 7465
2022
Q2 		$18K Buy
1,000
+57
+6% +$1.3K ﹤0.01% 7021
2022
Q1 		$28K Sell
943
-770
-45% -$24.6K ﹤0.01% 7073
2021
Q4 		$74K Buy
1,713
+227
+15% +$13.1K ﹤0.01% 6561
2021
Q3 		$105K Sell
1,486
-853
-36% -$78.4K ﹤0.01% 5795
2021
Q2 		$268K Sell
2,339
-379
-14% -$37K ﹤0.01% 5150
2021
Q1 		$282K Buy
2,718
+933
+52% +$88.6K ﹤0.01% 5250
2020
Q4 		$86K Buy
1,785
+163
+10% +$5.98K ﹤0.01% 5784
2020
Q3 		$45K Sell
1,622
-572
-26% -$16.4K ﹤0.01% 5724
2020
Q2 		$83K Buy
2,194
+87
+4% +$4.49K ﹤0.01% 5444
2020
Q1 		$103K Sell
2,107
-662
-24% -$32.5K ﹤0.01% 5266
2019
Q4 		$124K Buy
2,769
+619
+29% +$22.3K ﹤0.01% 5893
2019
Q3 		$91K Buy
2,150
+798
+59% +$31.4K ﹤0.01% 5817
2019
Q2 		$68K Buy
1,352
+230
+20% +$19.1K ﹤0.01% 5662
2019
Q1 		$88K Buy
1,122
+1,032
+1,147% +$66.5K ﹤0.01% 5162
2018
Q4 		$2K Buy
+90
New +$3.24K ﹤0.01% 7805
2018
Q3 		– Sell
-19
Closed -$1K – 8169
2018
Q2 		$1K Sell
19
-275
-94% -$13.5K ﹤0.01% 7827
2018
Q1 		$12K Buy
294
+34
+13% +$2.25K ﹤0.01% 6762
2017
Q4 		$24K Buy
260
+232
+829% +$26.2K ﹤0.01% 6410
2017
Q3 		$4K Sell
28
-65
-70% -$6.81K ﹤0.01% 7316
2017
Q2 		$10K Buy
93
+88
+1,760% +$10K ﹤0.01% 6775
2017
Q1 		$1K Sell
5
-30
-86% -$3.46K ﹤0.01% 7438
2016
Q4 		$5K Buy
35
+31
+775% +$3.41K ﹤0.01% 7246
2016
Q3 		$0 Sell
4
-3
-43% -$242 ﹤0.01% 7857
2016
Q2 		$0 Buy
7
+1
+17% +$93 ﹤0.01% 7898
2016
Q1 		$1K Buy
+6
New +$531 ﹤0.01% 7441

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

UBS Group's IMDX Position: Q1 2026 in Review

UBS Group increased its Insight Molecular Diagnostics (IMDX) stake by 674% in Q1 2026, buying an estimated $115K and bringing the position to 22,751 shares worth $74.6K. The position accounts for ﹤0.01% of the portfolio, ranked #7140.

UBS Group first reported a position in IMDX in Q1 2016 and has held it in 40 quarters since. The position peaked at $282K in Q1 2021. 41 funds tracked by Wall St. Rank hold IMDX as of Q1 2026.

  • UBS Group held 22,751 shares of Insight Molecular Diagnostics worth $74.6K as of Q1 2026.
  • UBS Group bought 19,810 Insight Molecular Diagnostics shares in Q1 2026, an estimated $115K.
  • Insight Molecular Diagnostics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7140 holding.
  • UBS Group first reported a position in Insight Molecular Diagnostics in Q1 2016 and has held it in 40 quarters since.
  • UBS Group's Insight Molecular Diagnostics position peaked at $282K in Q1 2021.
  • 41 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.